Publication Name	World Journal of Hepatology
Manuscript ID	11887
Country	Japan

Received	2014-06-11 08:43
Peer-Review Started	2014-06-11 13:34
To Make the First Decision	2014-08-14 14:40
Return for Revision	2014-08-18 08:52
Revised	2014-08-27 11:00
Second Decision	2014-09-17 13:59
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-09-17 14:25
Articles in Press	2014-09-17 14:25
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-11-20 09:16
Publish the Manuscript Online	2014-11-20 19:46

ISSN	1948-5182 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Case Report
Article Title	Hemodynamic effects of ambrisentan-tadalafil combination therapy on progressive portopulmonary hypertension
Manuscript Source	Unsolicited Manuscript
All Author List	Yu Yamashita, Ichizo Tsujino, Takahiro Sato, Asuka Yamada, Taku Watanabe, Hiroshi Ohira and Masaharu Nishimura
Funding Agency and Grant Number
Corresponding Author	Ichizo Tsujino, MD, PhD, First Department of Medicine, Hokkaido University Hospital N14, W5, Kita-ku, Sapporo, Hokkaido 060-8648, Japan. itsujino@med.hokudai.ac.jp
Key Words	Portopulmonary hypertension; Ambrisentan; Tadalafil; Thrombocytopenia
Core Tip	Advanced liver dysfunction and/or thrombocytopenia often hamper the use of intravenous epoprostenol in patients with portopulmonary hypertension (PoPH). However, recent progress in the oral treatment for pulmonary hypertension (PH) has enabled better clinical outcome in severe PH patients. Here we report two World Health Organization functional class IV patients with PoPH and thrombocytopenia who were successfully treated with ambrisentan and tadalafil. Oral vasodilator therapy using a combination of ambrisentan and tadalafil may be a safe and effective therapeutic option for patients with PoPH and advanced thrombocytopenia.
Publish Date	2014-11-20 19:46
Citation	Yamashita Y, Tsujino I, Sato T, Yamada A, Watanabe T, Ohira H, Nishimura M. Hemodynamic effects of ambrisentan-tadalafil combination therapy on progressive portopulmonary hypertension. World J Hepatol 2014; 6(11): 825-829
URL	http://www.wjgnet.com/1948-5182/full/v6/i11/825.htm
DOI	http://dx.doi.org/10.4254/wjh.v6.i11.825

Full Article (PDF)	WJH-6-825.pdf
Full Article (Word)	WJH-6-825.doc
Manuscript File	11887-Review.docx
Answering Reviewers	11887-Answering reviewers.pdf
Copyright License Agreement	11887-Copyright assignment.pdf
Institutional Review Board Approval Form or Document	Ethics_Committee_20140610124441.pdf
Non-Native Speakers of English Editing Certificate	11887-Language certificate.pdf
Peer-review Report	11887-Peer review(s).pdf
Scientific Misconduct Check	11887-CrossCheck.jpg
Scientific Editor Work List	11887-Scientific editor work list.pdf